Pritumumab is under clinical development by Nascent Biotech and currently in Phase I for Glioma. According to GlobalData, Phase I drugs for Glioma have an 81% phase transition success rate (PTSR) ...
Lab-grown minibrains, remarkable brain scans and psychedelic trips — take a look back at some of Live Science's most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback